Cell and gene therapies in epilepsy--promising avenues or blind alleys?

Trends in Neurosciences
Wolfgang LöscherUwe Heinemann

Abstract

The past decades have brought several advances to the treatment of epilepsy. However, despite the continued development and release of new antiepileptic drugs (AEDs), more than one-third of patients are resistant to pharmacological treatment. Furthermore, current AEDs do not prevent the development and progression of epilepsy. Thus, there is an urgent need to develop new therapies for AED-resistant patients, for prevention of epilepsy in patients at risk and for disease modification. Cell replacement and gene therapies have been proposed to offer potential approaches for improvements in therapy, but are such approaches really more promising than new pharmacological strategies? Here we critically review and discuss data from epilepsy models and human tissue studies indicating that cell and gene therapies might provide alternative therapeutic approaches for AED-resistant focal epilepsies and might have antiepileptogenic or disease-modifying potential. However, several crucial issues remain to be resolved to develop cell and gene therapies into effective and safe therapies.

References

Dec 17, 1991·Brain Research. Developmental Brain Research·G L HolmesG F Carl
Jul 1, 1989·Experimental Neurology·G BuzsákiF H Gage
Dec 1, 1987·Proceedings of the National Academy of Sciences of the United States of America·D I BarryO Lindvall
Dec 1, 1988·Proceedings of the National Academy of Sciences of the United States of America·G BuzsákiF H Gage
Dec 1, 1996·Progress in Neurobiology·W Löscher, U Ebert
Sep 30, 1998·The European Journal of Neuroscience·I FerenczO Lindvall
Aug 11, 2000·Transplantation Proceedings·A S Edge
Jun 19, 2001·Proceedings of the National Academy of Sciences of the United States of America·A HuberD Boison
Mar 7, 2002·Trends in Pharmacological Sciences·Wolfgang Löscher
Oct 16, 2002·Molecular Therapy : the Journal of the American Society of Gene Therapy·Rebecca HabermanThomas McCown
Oct 29, 2002·Annals of Neurology·Yilong MaDavid Eidelberg
Nov 19, 2003·The European Journal of Neuroscience·En-Ju D LinMatthew J During
Dec 4, 2003·Epilepsy Research·Dieter Schmidt, Wolfgang Löscher
Dec 25, 2003·Epilepsia·Kerry W Thompson, Lucie M Suchomelova
Mar 27, 2004·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Cristina RichichiAnnamaria Vezzani
Jun 15, 2004·Progress in Neurobiology·Kiyoshi MorimotoRonald J Racine
Jun 23, 2004·Nature Reviews. Neuroscience·Michael A Rogawski, Wolfgang Löscher
Jun 25, 2004·Neurosurgery·Toshinori HasegawaElaine Elder
Oct 27, 2004·Expert Opinion on Biological Therapy·Thomas J McCown
Feb 5, 2005·Cell Transplantation·Douglas KondziolkaMichael McGrogan
Feb 18, 2005·NeuroRx : the Journal of the American Society for Experimental NeuroTherapeutics·Roger A Barker, Håkan Widner
Mar 26, 2005·Current Opinion in Neurology·Yehezkel Ben-Ari, Gregory L Holmes
Aug 2, 2005·Epilepsy Currents·Annamaria Vezzani
Aug 27, 2005·Journal of Neurosurgery·Douglas KondziolkaJeffrey Teraoka
Sep 16, 2005·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Ashok K ShettyBharathi Hattiangady
Feb 28, 2006·Molecular Therapy : the Journal of the American Society of Gene Therapy·Jennifer M LaingLaure Aurelian
Mar 15, 2006·Expert Review of Neurotherapeutics·Patrick Kwan, Martin J Brodie

❮ Previous
Next ❯

Citations

Apr 1, 2009·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Xu MaisanoJanice R Naegele
Apr 1, 2009·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Detlev Boison
Apr 28, 2009·Epilepsy Currents·Graeme J Sills
Sep 6, 2011·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Ashok K Shetty
Apr 1, 2009·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Michael A Rogawski, Gregory L Holmes
Apr 1, 2009·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Kerry Thompson
Apr 1, 2009·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Arnold R Kriegstein, Asla Pitkänen
Mar 17, 2010·Epilepsy Currents·Carl E Stafstrom
Jan 1, 2009·Expert Opinion on Drug Discovery·Doru Georg Margineanu, Henrik Klitgaard
Oct 11, 2015·Journal of Drug Targeting·Mehdi Kazemzadeh-NarbatAli Khademhosseini
Jan 10, 2016·Neuroscience and Biobehavioral Reviews·Ashok K Shetty, Dinesh Upadhya
Apr 7, 2015·Journal of Neuroscience Methods·Jan A GorterFernando H Lopes da Silva
Oct 2, 2015·Acta Neuropathologica·Annamaria VezzaniWolfgang Löscher
Sep 11, 2010·Epilepsy Research·Massimo MantegazzaSilvana Franceschetti
Aug 24, 2010·Seminars in Pediatric Neurology·Lucyna Zawadzki, Carl E Stafstrom
Nov 17, 2009·Neuroscience Letters·Revaz SolomoniaTamar Kiguradze
Jun 16, 2009·Epilepsy Research·Merab Kokaia
May 23, 2009·Experimental Neurology·Cory SzybalaDetlev Boison
Jun 3, 2008·Biomaterials·Andrew WilzDetlev Boison
Feb 1, 2011·Epilepsia·Panos TheofilasDetlev Boison
Aug 18, 2009·Biochemical Pharmacology·Detlev Boison, Kerry-Ann Stewart
Apr 26, 2011·Seizure : the Journal of the British Epilepsy Association·Annelies Van DyckePaul Boon
Jun 25, 2010·Cell Transplantation·Jana Mejía-ToiberMagda Giordano
Sep 19, 2012·Cellular and Molecular Neurobiology·Revaz SolomoniaTamar Kiguradze
Sep 14, 2011·Current Protocols in Stem Cell Biology·Bharathi Hattiangady, Ashok K Shetty
Jun 14, 2018·Frontiers in Cellular Neuroscience·Chiara FalcicchiaGianluca Verlengia
Dec 19, 2018·Proceedings of the National Academy of Sciences of the United States of America·Dinesh UpadhyaAshok K Shetty
Dec 2, 2020·Pharmaceutics·Manuela Gernert, Malte Feja

❮ Previous
Next ❯

Related Concepts

Related Feeds

Basal ganglia in Parkinson's disease (MDS)

The basal ganglia is comprised of the neostriatum, the external and internal pallidal segments, the subthalamic nucleus, the substantia nigra pars reticulata, and the pars compacta of the substantia nigra. The basal ganglia circuitry is responsible for the correct execution of voluntary movements and is implicated in Parkinson's disease. Here is the latest research investigating the basal ganglia in Parkinson's disease.

Cell-Type-Specific Viral Vectors (ASM)

Viral vectors are used in biological research and therapy to deliver genetic material into cells. However, the efficiency of viral vectors varies depending on the cell type. Here is the latest research on cell-type-specific viral vectors.

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.

AAV-based Gene Therapy

Adeno-associated virus (AAV)-based gene therapy is a biological vector that is being researched to be used as a potential therapeutic option. This gene therapy is designed to insert fragments of DNA into targeted cells to help treat diseases, such as hemophilia a. Discover the latest research on AAV-based gene therapy here.

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.

Astrocytes in Parkinson Disease

Parkinson's disease (PD) is a neurodegenerative disorder caused by the progressive loss of dopaminergic neurons. Some PD-genes may be associated with astrocyte dysfunction. Discover the latest research on astrocytes in Parkinson's disease here.

Adult Stem Cells

Adult stem cells reside in unique niches that provide vital cues for their survival, self-renewal, and differentiation. They hold great promise for use in tissue repair and regeneration as a novel therapeutic strategies. Here is the latest research.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Amygdala and Midbrain Dopamine

The midbrain dopamine system is widely studied for its involvement in emotional and motivational behavior. Some of these neurons receive information from the amygdala and project throughout the cortex. When the circuit and transmission of dopamine is disrupted symptoms may present. Here is the latest research on the amygdala and midbrain dopamine.

Cell-Type Specific Viral Vectors

Viral vectors are used in biological research and therapy to deliver genetic material into cells. However, the efficiency of viral vectors varies depending on the cell type. Here is the latest research on cell-type-specific viral vectors.

Cell-Type-Specific Viral Vectors

Viral vectors are used in biological research and therapy to deliver genetic material into cells. However, the efficiency of viral vectors varies depending on the cell type. Here is the latest research on cell-type-specific viral vectors.

Amygdala: Sensory Processes

Amygdalae, nuclei clusters located in the temporal lobe of the brain, play a role in memory, emotional responses, and decision-making. Here is the latest research on sensory processes in the amygdala.

© 2021 Meta ULC. All rights reserved